Last reviewed · How we verify

kejiang Cao — Portfolio Competitive Intelligence Brief

kejiang Cao pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Shensong Yangxin capsule Shensong Yangxin capsule marketed Traditional Chinese medicine herbal formulation Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
  2. China Academy of Chinese Medical Sciences · 1 shared drug class
  3. Dongzhimen Hospital, Beijing · 1 shared drug class
  4. Jinling Hospital, China · 1 shared drug class
  5. Liaoning University of Traditional Chinese Medicine · 1 shared drug class
  6. Peking Union Medical College Hospital · 1 shared drug class
  7. Qilu Hospital of Shandong University · 1 shared drug class
  8. Shanghai Institute of Hypertension · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for kejiang Cao:

Cite this brief

Drug Landscape (2026). kejiang Cao — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kejiang-cao. Accessed 2026-05-17.

Related